Multiplex Tissue Imaging Harmonization: A Multicenter Experience from CIMAC-CIDC Immuno-Oncology Biomarkers Network
Open Access
- 15 September 2021
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 27 (18), 5072-5083
- https://doi.org/10.1158/1078-0432.CCR-21-2051
Abstract
Purpose: The Cancer Immune Monitoring and Analysis Centers - Cancer Immunologic Data Commons (CIMAC-CIDC) network supported by the NCI Cancer Moonshot initiative was established to provide correlative analyses for clinical trials in cancer immunotherapy, using state-of-the-art technology. Fundamental to this initiative is implementation of multiplex IHC assays to define the composition and distribution of immune infiltrates within tumors in the context of their potential role as biomarkers. A critical unanswered question involves the relative fidelity of such assays to reliably quantify tumor-associated immune cells across different platforms. Experimental Design: Three CIMAC sites compared across their laboratories: (i) image analysis algorithms, (ii) image acquisition platforms, (iii) multiplex staining protocols. Two distinct high-dimensional approaches were employed: multiplexed IHC consecutive staining on single slide (MICSSS) and multiplexed immunofluorescence (mIF). To eliminate variables potentially impacting assay performance, we completed a multistep harmonization process, first comparing assay performance using independent protocols followed by the integration of laboratory-specific protocols and finally, validating this harmonized approach in an independent set of tissues. Results: Data generated at the final validation step showed an intersite Spearman correlation coefficient (r) of >= 0.85 for each marker within and across tissue types, with an overall low average coefficient of variation <= 0.1. Conclusions: Our results support interchangeability of protocols and platforms to deliver robust, and comparable data using similar tissue specimens and confirm that CIMAC-CIDC analyses may therefore be used with confidence for statistical associations with clinical outcomes largely independent of site, antibody selection, protocol, and platform across different sites.Funding Information
- National Cancer Institute (U24CA224319)
- National Cancer Institute (U24CA224331)
- National Cancer Institute (U24CA224285)
This publication has 26 references indexed in Scilit:
- Recent developments in multiplexing techniques for immunohistochemistryExpert Review of Molecular Diagnostics, 2015
- Quantitative measurement of cancer tissue biomarkers in the lab and in the clinicLaboratory Investigation, 2015
- PD-1 blockade induces responses by inhibiting adaptive immune resistanceNature, 2014
- Principles of Analytic Validation of Immunohistochemical Assays: Guideline From the College of American Pathologists Pathology and Laboratory Quality CenterArchives of Pathology & Laboratory Medicine, 2014
- Evaluation of the effectiveness of Gaussian filtering in distinguishing punctate synaptic signals from background noise during image analysisJournal of Neuroscience Methods, 2014
- Applications of mass spectrometry for quantitative protein analysis in formalin‐fixed paraffin‐embedded tissuesProteomics, 2013
- Quality control by tissue microarray in immunohistochemistry: Figure 1Journal of Clinical Pathology, 2012
- On-tissue protein identification and imaging by MALDI-Ion mobility mass spectrometryJournal of the American Society for Mass Spectrometry, 2010
- Recommendations for Improved Standardization of ImmunohistochemistryApplied Immunohistochemistry & Molecular Morphology, 2007
- A Multiplex Tissue Immunoblotting Assay for Proteomic Profiling: A Pilot Study of the Normal to Tumor Transition of Esophageal Squamous Cell CarcinomaCancer Epidemiology, Biomarkers & Prevention, 2006